Primaquine: The risks and the benefits

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Ashley, Elizabeth A ^a,b   Recht, Judith ^a   White, Nicholas J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

G6PD deficiency; Haemolysis; Malaria; Primaquine

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; PRIMAQUINE; ANTIMALARIAL AGENT;

ABNORMAL URINE COMPOSITION; ALLERGIC REACTION; BLACK URINE; DARK URINE; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GENETIC VARIABILITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; IN VIVO STUDY; INTRAVASCULAR HEMOLYSIS; JAUNDICE; KIDNEY FAILURE; LIVER NECROSIS; MALARIA FALCIPARUM; MENTAL DISEASE; METHEMOGLOBINEMIA; MORTALITY; NEUROLOGIC DISEASE; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; MALARIA, FALCIPARUM;

ANTIMALARIALS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMANS; MALARIA, FALCIPARUM; PRIMAQUINE;

EID: 84920774125     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-418     Document Type: Review

References (42)

1. Recht J, Ashley EA, White NJ: Safety of 8-Aminoquinoline Antimalarial Medicines. Geneva: World Health Organization; 2014. Downloadable at: http://www.who.int/malaria/publications/atoz/9789241506977/en/.
2. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE: Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: A preliminary report. Bull World Health Organ 1960, 22:621-631.
3. Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, Cao J, Kachur SP, Feachem RG, Gosling RD, Gao Q: Mass drug administration for the control and elimination of Plasmodium vivax malaria: An ecological study from Jiangsu province. China Malar J 2013, 12:383.
4. Kondrashin AV, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VM: Mass primaquine treatment to eliminate vivax malaria; lessons from the past. Malar J 2014, 13:51.
5. Garfield RM, Vermund SH: Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 1983, 2:500-503.
6. Kumar A, Valecha N, Jain T, Dash AP: Burden of malaria in India: retrospective and prospective view. Am J Trop Med Hyg 2007, 77:69-78.
7. World Health Organization: Single Dose Primaquine as a Gametocytocide in Plasmodium Falciparum Malaria; Updated WHO Policy Recommendation. Geneva: World Health Organization; 2012. http://www.who.int/malaria/publications/atoz/who-pq-policy-recommendation/en/.
8. Barrett O Jr, Skrzypek G, Datel W, Goldstein JD: Malaria imported to the United States from Vietnam. Chemoprophylaxis evaluated in returning soldiers. Am J Trop Med Hyg 1969, 18:495-499.
9. White NJ, Qiao LG, Qi G, Luzzatto L: Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012, 11:418.
10. White NJ: Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013, 13:175-181.
11. Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, Bradley J, Grignard L, Lanke KH, Wanzira H, Mpimbaza A, Nsobya S, White NJ, Webb EL, Staedke SG, Drakeley C: Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: A randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014, 14:130-139.
12. Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008, 371:64-74.
13. Luzzatto L, Poggi V: Glucose-6-phosphate dehydrogenase deficiency. In Nathan and Oski's Hematology of infancy and childhood. 7th edition. Edited by Orkin. Canada: Saunders; 2009:Chapter 17.
14. Beutler E: G6PD deficiency. Blood 1994, 84:3613-3636.
15. Dern RJ, Beutler E, Alving AS: The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 1954, 44:171-176.
16. Kellermeyer RW, Tarlov AR, Schrier SL, Carson PE, Alving AS: The hemolytic effect of primaquine. XIII. Gradient susceptibility to hemolysis of primaquine-sensitive erythrocytes. J Lab Clin Med 1961, 58:225-233.
17. Ziai M, Amirhakimi GH, Reinhold JG, Tabatabee M, Gettner ME, Bowman JE: Malaria prophylaxis and treatment in G-6-PD deficiency. An observation on the toxicity of primaquine and chloroquine. Clin Pediatr (Phila) 1967, 6:242-243.
18. Pannacciulli I, Salvidio E, Tizianello A, Parravidino G: Hemolytic effects of standard single dosages of primaquine and chloroquine on G-6-PD-deficient caucasians. J Lab Clin Med 1969, 74:653-661.
19. Beutler E, Duparc S: Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 2007, 77:779-789.
20. Alvin R, Tarlov MD, George J, Carlson PE, Alving AS: Primaquine sensitivity. Arch Int Med 1962, 109:137-162.
21. Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS: Hemolytic effect of therapeutic drugs. Clinical considerations of the primaquine-Type hemolysis. JAMA 1962, 180:388-394.
22. Everett WD, Yoshida A, Pearlman E: Haemoglobin E and glucose-6-phosphate deficiency in the Khmer Air Force (Cambodia). Am J Trop Med Hyg 1977, 26:597-601.
23. Buchachart K, Krudsood S, Singhasivanon P, Treeprasertsuk S, Phophak N, Srivilairit S, Chalermrut K, Rattanapong Y, Supeeranuntha L, Wilairatana P, Brittenham G, Looareesuwan S: Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health 2001, 32:720-726.
24. Charoenlarp P, Areekul S, Harinasuta T, Sirivorasarn P: The haemolytic effect of a single dose of 45 mg of primaquine in G-6-PD deficient Thais. J Med Assoc Thai 1972, 55:631-638.
25. Sukumar S, Colah R, Mohanty D: G6PD gene mutations in India producing drug-induced haemolytic anaemia. Br J Haematol 2002, 116:671-672.
26. Abeyaratne KP, Halpe NL: Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. Ceylon Med J 1968, 13:134-138.
27. Kondrashin AV, Lopuchina NG, Gozodova GE, Abdullaev HI, Bagramyan MG, Mirsiabov AY, Averkiev LI, Vainstein AM, Kvitko MA, Prodeus TV, Jafarov AD, Nusratov GN: Organization of the Mass Prophylactic Treatment with Primaquine of the population in the active malaria foci in Azerbaijan. In Actual Problems of Malaria Prophylaxis in the USSR (Materials of the Inter-Republican Conference, Lencoran, Baku 24-26 April 1973; 84-90 (in Russian). Baku: 1973.
28. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M: A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province. Pakistan PLoS One 2008, 3:e2861.
29. World Health Organization: Guidelines for the Treatment of Malaria. http://www.who.int/malaria/publications/atoz/9789241547925/en/.
30. Nosten F, Imvithaya S, Vincenti M, Delmas G, Lebihan G, Hausler B, White N: Malaria on the Thai-Burmese border: Treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine. Bull World Health Organ 1987, 65:891-896.
31. Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T: In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 2010, 54:1762-1768.
32. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ: Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: An open-label randomised trial. Lancet Infect Dis 2010, 10:673-681.
33. Eziefula AC, Pett H, Grignard L, Opus S, Kiggundu M, Kamya MR, Yeung S, Staedke SG, Bousema T, Drakeley C: Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine. Antimicrob Agents Chemother 2014, 58:4971-4973.
34. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V: CYP450 phenotyping and accurate mass identification of metabolites of the 8-Aminoquinoline, anti-malarial drug primaquine. Malar J 2012, 11:259.
35. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V: The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013, 12:212.
36. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF: Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013, 369:1381-1382.
37. Aung-Than-Batu, Hla-Pe U, Thein-Than: Primaquine induced haemolysis in G-6-PD deficient Burmese. Trans R Soc Trop Med Hyg 1970, 64:785-786.
38. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor WR, Baird JK, Menard D: Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One 2011, 6:e28357.
39. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN: Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008, 46:1374-1381.
40. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, Warikar N, Sugiarto P, Tjitra E, Anstey NM, Price RN: Vivax malaria: A major cause of morbidity in early infancy. Clin Infect Dis 2009, 48:1704-1712.
41. White NJ: Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011, 10:297.
42. Graves PM, Gelband H, Garner P: Primaquine or other 8-Aminoquinoline for reducing P. falciparum transmission. Cochrane Database Syst Rev 2014, 6:CD008152.